Controlled release of free doxorubicin from peptide-drug conjugates by drug loading

Journal of Controlled Release

Volumn 191, Issue , 2014, Pages 123-130

  Chen, Zhipeng ^a,b,c   Zhang, Pengcheng ^b   Cheetham, Andrew G ^b   Moon, Jae Hyon ^b   Moxley, James W ^b   Lin, Yi An ^b   Cui, Honggang ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Johns Hopkins University   (United States)

^c China Pharmaceutical University   (China)

Author keywords

Chemotherapy; Controlled release; Doxorubicin; Drug conjugate; Drug delivery

Indexed keywords

CANCER CELLS; CELLS; CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; PEPTIDES; TARGETED DRUG DELIVERY;

CELLULAR UPTAKE; CONTROLLED RELEASE; COVALENT MODIFICATIONS; DOXORUBICIN; DRUG LOADING; DRUG-CONJUGATES; DRUG-RELEASE RATE; INTRACELLULAR ACCUMULATION; PEPTIDE DRUGS; RELEASE RATE;

CHEMOTHERAPY;

BETA ALANINE MALEIMIDE; CATHEPSIN B; CELL PENETRATING PEPTIDE; CELL PENETRATING PEPTIDE TAT; DOXORUBICIN; DRUG CARRIER; GLYCYLPHENYLALANYLLEUCYLGLYCINE; TETRAPEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DELAYED RELEASE FORMULATION; PEPTIDE FRAGMENT; PRODRUG; TRANSACTIVATOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG SYNTHESIS; DRUG UPTAKE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; KINETICS; LIVER TUMOR; MEDICINAL CHEMISTRY; METABOLISM; PATHOLOGY; PHARMACEUTICS; SOLUBILITY;

ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG CARRIERS; HEP G2 CELLS; HUMANS; KINETICS; LIVER NEOPLASMS; PEPTIDE FRAGMENTS; PRODRUGS; SOLUBILITY; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84906951200     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.051     Document Type: Article

References (66)

1. R. Duncan, Polymer conjugates as anticancer nanomedicines, Nat. Rev. Cancer 6 (2006) 688-701.
2. M.M. Gottesman, Mechanisms of cancer drug resistance, Annu. Rev.Med. 53 (2002) 615-627.
3. H.S. Oberoi, N.V. Nukolova, A.V. Kabanov, T.K. Bronich, Nanocarriers for delivery of platinum anticancer drugs, Adv. Drug Deliv. Rev. 65 (2013) 1667-1685.
4. W. Arap, R. Pasqualini, E. Ruoslahti, Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model, Science 279 (1998) 377-380.
5. L.W. Seymour, K. Ulbrich, P.S. Steyger, M. Brereton, V. Subr, J. Strohalm, R. Duncan, Tumor tropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16f10 melanoma, Br. J. Cancer 70 (1994) 636-641.
6. J.A. MacKay, M.N. Chen, J.R. McDaniel, W.G. Liu, A.J. Simnick, A. Chilkoti, Selfassembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection, Nat. Mater. 8 (2009) 993-999.
7. E.A. Dubikovskaya, S.H. Thorne, T.H. Pillow, C.H. Contag, P.A. Wender, Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 12128-12133.
8. V.M. Ahrens, K. Bellmann-Sickert, A.G. Beck-Sickinger, Peptides and peptide conjugates: Therapeutics on the upward path, Future Med. Chem. 4 (2012) 1567-1586.
9. Y. Gao, Y. Kuang, Z.F. Guo, Z.H. Guo, I.J. Krauss, B. Xu, Enzyme-instructed molecular self-assembly confers nanofibers and a supramolecular hydrogel of taxol derivative, J. Am. Chem. Soc. 131 (2009) 13576-13577.
10. C.B. Yang, D.X. Li, Q.Q. FengZhao, L.Y. Wang, L. Wang, Z.M. Yang, Disulfide bond reduction-triggered molecular hydrogels of folic acid Taxol conjugates, Org. Biomol. Chem. 11 (2013) 6946-6951.
11. A.G. Cheetham, P. Zhang, Y.A. Lin, L.L. Lock, H. Cui, Supramolecular nanostructures formed by anticancer drug assembly, J. Am. Chem. Soc. 135 (2013) 2907-2910.
12. R. Lin, A.G. Cheetham, P. Zhang, Y.A. Lin, H. Cui, Supramolecular filaments containing a fixed 41% paclitaxel loading, Chem. Commun. 49 (2013) 4968-4970.
13. J.R. McDaniel, J. Bhattacharyya, K.B. Vargo, W. Hassouneh, D.A. Hammer, A. Chilkoti, Self-assembly of thermally responsive nanoparticles of a genetically encoded peptide polymer by drug conjugation, Angew. Chem. 52 (2013) 1683-1687.
14. R. Tong, J. Cheng, Drug-initiated, controlled ring-opening polymerization for the synthesis of polymer-drug conjugates, Macromolecules 45 (2012) 2225-2232.
15. J. Zou, G. Jafr, E. Themistou, Y. Yap, Z.A.Wintrob, P. Alexandridis, A.C. Ceacareanu, C. Cheng, pH-sensitive brush polymer-drug conjugates by ring-opening metathesis copolymerization, Chem. Commun. 47 (2011) 4493-4495.
16. R. Tong, J. Cheng, Ring-opening polymerization-mediated controlled formulation of polylactide-drug nanoparticles, J. Am. Chem. Soc. 131 (2009) 4744-4754.
17. P.A. Vasey, S.B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A.H. Thomson, L. S. Murray, T.E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, J. Cassidy, Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee, Clin. Cancer Res. 5 (1999) 83-94.
18. J. Kopecek, P. Kopeckova, T. Minko, Z.R. Lu, HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action, Eur. J. Pharm. Biopharm. 50 (2000) 61-81.
19. C.C. Lee, E.R. Gillies, M.E. Fox, S.J. Guillaudeu, J.M. Frechet, E.E. Dy, F.C. Szoka, A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 16649-16654.
20. Y.E. Kurtoglu, M.K. Mishra, S. Kannan, R.M. Kannan, Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers, Int. J. Pharm. 384 (2010) 189-194.
21. S. Sunoqrot, Y. Liu, D.H. Kim, S. Hong, In vitro evaluation of dendrimer-polymer hybrid nanoparticles on their controlled cellular targeting kinetics, Mol. Pharm. 10 (2013) 2157-2166.
22. O.L. Padilla De Jesus, H.R. Ihre, L. Gagne, J.M. Frechet, F.C. Szoka Jr., Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation, Bioconjug. Chem. 13 (2002) 453-461.
23. D.A. Modi, S. Sunoqrot, J. Bugno, D.D. Lantvit, S. Hong, J.E. Burdette, Targeting of follicle stimulating hormone peptide-conjugated dendrimers to ovarian cancer cells, Nanoscale 6 (2014) 2812-2820.
24. L. Vigderman, E.R. Zubarev, Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules, Adv. Drug Deliv. Rev. 65 (2013) 663-676.
25. Y. Cheng, J.D. Meyers, A.M. Broome, M.E. Kenney, J.P. Basilion, C. Burda, Deep penetration of a pdt drug into tumors by noncovalent drug-gold nanoparticle conjugates, J. Am. Chem. Soc. 133 (2011) 2583-2591.
26. F. Wang, Y.C. Wang, S. Dou, M.H. Xiong, T.M. Sun, J. Wang, Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells, ACS Nano 5 (2011) 3679-3692.
27. H.P. Rang, M.M. Dale, Rang and Dale's pharmacology, 7th ed. Churchill Livingstone, Edinburgh, 2012. xxii (777 pp.).
28. R. Langer, New methods of drug delivery, Science 249 (1990) 1527-1533.
29. S. Aryal, C.M. Hu, L. Zhang, Combinatorial drug conjugation enables nanoparticle dual-drug delivery, Small 6 (2010) 1442-1448.
30. Y. Yu, C.K. Chen, W.C. Law, J.Mok, J. Zou, P.N. Prasad, C. Cheng, Well-defined degradable brush polymer-drug conjugates for sustained delivery of Paclitaxel, Mol. Pharm. 10 (2013) 867-874.
31. Q. Yin, R. Tong, L. Yin, T.M. Fan, J. Cheng, Anticancer camptothecin-N-poly(lactic acid) nanoconjugates with facile hydrolysable linker, Polym. Chem. 5 (2014) 1581-1585.
32. Q. Yin, R. Tong, Y. Xu, K. Baek, L.W. Dobrucki, T.M. Fan, J. Cheng, Drug-initiated ringopening polymerization of O-carboxyanhydrides for the preparation of anticancer drug-poly(O-carboxyanhydride) nanoconjugates, Biomacromolecules 14 (2013) 920-929.
33. C.H. Lee, S.H. Cheng, I.P. Huang, J.S. Souris, C.S. Yang, C.Y. Mou, L.W. Lo, Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics, Angew. Chem. Int. Ed. Engl. 49 (2010) 8214-8219.
34. D.Y. Furgeson, M.R. Dreher, A. Chilkoti, Structural optimization of a "smart" doxorubicin- polypeptide conjugate for thermally targeted delivery to solid tumors, J. Control. Release 110 (2006) 362-369.
35. S. Aryal, C.M. Hu, L. Zhang, Polymer-cisplatin conjugate nanoparticles for acidresponsive drug delivery, ACS Nano 4 (2010) 251-258.
36. X.L. Hu, J. Tian, T. Liu, G.Y. Zhang, S.Y. Liu, Photo-triggered release of caged camptothecin prodrugs from dually responsive shell cross-linked micelles, Macromolecules 46 (2013) 6243-6256.
37. J.R. Junutula, H. Raab, S. Clark, S. Bhakta, D.D. Leipold, S.Weir, Y. Chen, M. Simpson, S. P. Tsai, M.S. Dennis, Y.M. Lu, Y.G.Meng, C. Ng, J.H. Yang, C.C. Lee, E. Duenas, J. Gorrell, V. Katta, A. Kim, K. McDorman, K. Flagella, R. Venook, S. Ross, S.D. Spencer, W.L. Wong, H.B. Lowman, R. Vandlen, M.X. Sliwkowski, R.H. Scheller, P. Polakis, W. Mallet, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index, Nat. Biotechnol. 26 (2008) 925-932.
38. I.J. Majoros, A. Myc, T. Thomas, C.B. Mehta, J.R. Baker Jr., PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality, Biomacromolecules 7 (2006) 572-579.
39. D. Gabriel, M.F. Zuluaga, H. van den Bergh, R. Gurny, N. Lange, It is all about proteases: from drug delivery to in vivo imaging and photomedicine, Curr. Med. Chem. 18 (2011) 1785-1805.
40. S. Penugonda, A. Kumar, H.K. Agarwal, K. Parang, R. Mehvar, Synthesis and in vitro characterization of novel dextran-methylprednisolone conjugates with peptide linkers: effects of linker length on hydrolytic and enzymatic release of methylprednisolone and its peptidyl intermediates, J. Pharm. Sci. 97 (2008) 2649-2664.
41. L.L. Lock, A.G. Cheetham, P.C. Zhang, H.G. Cui, Design and construction of supramolecular nanobeacons for enzyme detection, ACS Nano 7 (2013) 4924-4932.
42. P.C. Zhang, A.G. Cheetham, L.L. Lock, H.G. Cui, Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site, Bioconjug. Chem. 24 (2013) 604-613.
43. E. Vives, P. Brodin, B. Lebleu, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus, J. Biol. Chem. 272 (1997) 16010-16017.
44. H. Brooks, B. Lebleu, E. Vives, Tat peptide-mediated cellular delivery: back to basics, Adv. Drug Deliv. Rev. 57 (2005) 559-577.
45. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, L. Gianni, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol. Rev. 56 (2004) 185-229.
46. K. Hong, A. Khwaja, E. Liapi, M.S. Torbenson, C.S. Georgiades, J.F.H. Geschwind, New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer, Clin. Cancer Res. 12 (2006) 2563-2567.
47. L.J. Goldstein, H. Galski, A. Fojo, M.Willingham, S.L. Lai, A. Gazdar, R. Pirker, A. Green, W. Crist, G.M. Brodeur, M. Lieber, J. Cossman, M.M. Gottesman, I. Pastan, Expression of a multidrug resistance gene in human cancers, J. Natl. Cancer Inst. 81 (1989) 116-124.
48. M.M. Gottesman, T. Fojo, S.E. Bates, Multidrug resistance in cancer: role of ATPdependent transporters, Nat. Rev. Cancer 2 (2002) 48-58.
49. P. Zhang, L.L. Lock, A.G. Cheetham, H. Cui, Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment, Mol. Pharm. 11 (2014) 964-973.
50. M.P. Borgman, A. Ray, R.B. Kolhatkar, E.A. Sausville, A.M. Burger, H. Ghandehari, Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy, Pharm. Res. 26 (2009) 1407-1418.
51. M. Marsh, A. Helenius, Adsorptive endocytosis of Semliki forest virus, J. Mol. Biol. 142 (1980) 439-454.
52. D. Wustner, M. Mondal, A. Huang, F.R. Maxfield, Different transport routes for high density lipoprotein and its associated free sterol in polarized hepatic cells, J. Lipid Res. 45 (2004) 427-437.
53. E.D. Schwoebel, T.H. Ho, M.S.Moore, Themechanismof inhibition of Ran-dependent nuclear transport by cellular ATP depletion, J. Cell Biol. 157 (2002) 963-974.
54. T.W. Chu, J.Y. Yang, J. Kopecek, Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis, Biomaterials 33 (2012) 7174-7181.
55. N.N. Yang, Z.Y. Ye, F. Li, R.I. Mahato, HPMA polymer-based site-specific delivery of oligonucleotides to hepatic stellate cells, Bioconjug. Chem. 20 (2009) 213-221.
56. D. Musil, D. Zucic, D. Turk, R.A. Engh, I. Mayr, R. Huber, T. Popovic, V. Turk, T. Towatari, N. Katunuma, et al., The refined 2.15 A X-ray crystal structure of human liver cathepsin B: The structural basis for its specificity, EMBO J. 10 (1991) 2321-2330.
57. J.P. Richard, K. Melikov, H. Brooks, P. Prevot, B. Lebleu, L.V. Chernomordik, Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors, J. Biol. Chem. 280 (2005) 15300-15306.
58. G.H. Li, W.X. Li, R.J. Mumper, A. Nath, Molecular mechanisms in the dramatic enhancement of HIV-1 Tat transduction by cationic liposomes, FASEB J. 26 (2012) 2824-2834.
59. K. Takayama, I. Nakase, H. Michiue, T. Takeuchi, K. Tomizawa, H. Matsui, S. Futaki, Enhanced intracellular delivery using arginine-rich peptides by the addition of penetration accelerating sequences (Pas), J. Control. Release 138 (2009) 128-133.
60. A.N. Shirazi, D. Oh, R.K. Tiwari, B. Sullivan, A. Gupta, G.D. Bothun, K. Parang, Peptide amphiphile containing arginine and fatty acyl chains as molecular transporters, Mol. Pharm. 10 (2013) 4717-4727.
61. D. Missirlis, T. Teesalu, M. Black, M. Tirrell, The non-peptidic part determines the internalization mechanism and intracellular trafficking of peptide amphiphiles, PLoS One 8 (2013) e54611.
62. T. Lehto, R. Abes, N. Oskolkov, J. Suhorutsenko, D.M. Copolovici, I. Mager, J.R. Viola, O. E. Simonson, K. Ezzat, P. Guterstam, E. Eriste, C.I.E. Smith, B. Lebleu, S. El Andaloussi, U. Langel, Delivery of nucleic acids with a stearylated (RxR)(4) peptide using a noncovalent co-incubation strategy, J. Control. Release 141 (2010) 42-51.
63. K. Zhang, R. Rossin, A. Hagooly, Z.Y. Chen, M.J. Welch, K.L. Wooley, Folate-mediated cell uptake of shell-crosslinked spheres and cylinders, J. Polym. Sci. A Polym. Chem. 46 (2008) 7578-7583.
64. M. Tyagi, M. Rusnati, M. Presta, M. Giacca, Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans, J. Biol. Chem. 276 (2001) 3254-3261.
65. A.Mishra, G.H. Lai, N.W. Schmidt, V.Z. Sun, A.R.Rodriguez, R. Tong, L. Tang, J.J.Cheng, T.J. Deming, D.T. Kamei, G.C.L. Wong, Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 16883-16888.
66. N. Teich, H. Bodeker, V. Keim, Cathepsin B cleavage of the trypsinogen activation peptide, BMC Gastroenterol. 2 (2002) 16.